Investment in resources to meet demand for large-scale supply of patented biocompatible surfactant

Pico-Surf offers reliable, highly stable and high-quality droplet generation and processing for microfluidic applications

Cambridge, UK, 13 February 2020: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, today announced investment in the production and supply of its proprietary biocompatible surfactant, Pico-Surf, for reliable and highly stable droplet generation and processing. Sphere Fluidics will expand operations to meet demand for large-scale commercial supply of its high-performing surfactant for use in a wide range of microfluidic application workflows.

Pico-Surf is a high-quality and animal-origin-free biocompatible surfactant optimized to support the formation of aqueous solution-in-oil picodroplets. Sphere Fluidics aims to increase production of Pico-Surf by three-fold in 2020, whilst maintaining its industry-leading standards, through significant investment of resources in manufacture and quality control processes, and workforce. As part of Sphere Fluidics’ range of specialist chemicals, Pico-Surf is designed to work effectively and flexibly across a broad range of microfluidic systems, including the Company’s proprietary single cell analysis platforms and applications, such as molecular biology assays, cell secretion assays and cell growth studies.

The unique and patented molecular structure of Pico-Surf stabilizes droplets, and retains and protects their cellular and molecular contents over a wide range of temperatures and biological conditions, helping to ensure high cell viability for improved assay performance. Droplets generated using Pico-Surf show low end point interfacial tension and critical micelle concentration in comparison to other commercially available surfactants. The purity and quality of the surfactant also enables a more efficient droplet sorting process at low voltage. The ready-to-use surfactant is available in large batches or made-to-order with ensured lot-to-lot consistency.

Dr. Marian Rehak, Vice President of Research and Development, Sphere Fluidics, said: “We are enthused by the increased demand for Pico-Surf, and eager to mobilize its production to meet demand. Whilst doing so, we will ensure its very high quality control standards are maintained, meaning researchers can continue rely on Pico-Surf to create droplets that are stable and reproducible.”

Rob Treanor, Director of Operations, Sphere Fluidics, commented: “Sphere Fluidics’ world-leading expertise in picodroplet technology has enabled the development of an ever-growing range of high-performing patented consumables, vital for the successful use of microfluidic systems. All our consumable products have been designed to be platform-agnostic, so they work effectively with a number of microfluidic systems.”

For further information on Pico-Surf, please visit: https://spherefluidics.com/specialist-chemicals/

For further information about Sphere Fluidics’ full range of consumables for microfluidics systems, please visit: https://spherefluidics.com/products/consumables/

ENDS

For further information please contact:

Sphere Fluidics

Dr Zoe Nilsson, Global Product Marketing Manager

Tel: +44 (0)1223 804210

Email: zoe.nilsson@spherefluidics.com

Zyme Communications

Dr Michelle Ricketts

Tel: +44 (0)778 9053 885

Email: michelle.ricketts@zymecommunications.com

About Sphere Fluidics www.spherefluidics.com

Sphere Fluidics develops and manufactures single cell analysis and monoclonality assurance systems to enable leading edge research and accelerate for biotherapeutic discovery and development.

The Company’s picodroplet incubation technology enables ultra-sensitive, rapid miniaturized assays of target protein secreted from tens of millions of individual cells.

Sphere Fluidics’ Cyto-Mine System integrates isolation, selective screening, sorting, imaging and clone verification into a single automated platform to streamline workflows, reduce costs, improve throughput and enable high-value clones to be captured in a single run. Cyto-Mine is underpinned by the Company’s patented picodroplet technology, which enables ultra-sensitive, rapid miniaturized assays of target protein secreted from tens of millions of individual cells.

Its Picodroplet Single Cell Analysis and Isolation System offers state-of-the-art microfluidics technology inside an easy-to-use, semi-automated system with variable parameters, to easily integrate into research processes.

Sphere Fluidics is located in Granta Park Cambridgeshire (UK) and Monmouth Junction, New Jersey (USA). The Company is also internationalizing its business via a global network of distributors.

Follow Sphere Fluidics on Twitter @SphereFluidics and LinkedIn @Sphere Fluidics Limited.